{
    "clinical_study": {
        "@rank": "24979", 
        "arm_group": {
            "arm_group_label": "Technosphere\u00ae Insulin (TI)", 
            "arm_group_type": "Experimental", 
            "description": "Inhalation Powder"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to allow patients with specific needs for inhaled insulin to\n      continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn\n      from the market."
        }, 
        "brief_title": "Patient Transitioning From Exubera\u00ae (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere\u00ae Insulin (Insulin Human [rDNA Origin]) Inhalation Powder", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 1 Diabetes", 
            "Type 2 Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Aspiration", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase 3, open label, multicenter, safety follow up trial to convert the treatment of\n      subjects currently using Exubera to treatment with TI Inhalation Powder"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has type 1 or type 2 diabetes mellitus and is currently being treated with or\n             has been treated with Exubera.\n\n          -  Subject has a severe phobia to sc injections of insulin (needle phobia) preventing\n             conventional treatment OR has impaired sc insulin absorption\n\n        Exclusion Criteria:\n\n          -  Smoking in the previous 6 months\n\n          -  History of asthma or chronic obstructive pulmonary disease (COPD) or any other\n             significant pulmonary disease, or exposure to pulmonary toxins.\n\n          -  Clinically significant pulmonary abnormalities on chest high-resolution computed\n             tomography (HRCT).\n\n          -  PFT results prior to transferring to TI Inhalation Powder showing any of the\n             following: FEV1 < 70% of predicted, FVC < 70% of predicted, DLCO < 70% of predicted,\n             TLC < 80% of predicted.\n\n          -  Allergy to insulin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798914", 
            "org_study_id": "MKC-TI-139"
        }, 
        "intervention": {
            "arm_group_label": "Technosphere\u00ae Insulin (TI)", 
            "description": "Inhalation Powder", 
            "intervention_name": "Technosphere\u00ae Insulin (TI) Inhalation Powder", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Montgomery", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36117"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montgomery", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36106"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orland Park", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60467"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "71105"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Annapolis", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21401"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norton", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02766"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portsmouth", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03801"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Great Neck", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11021"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Hyde Park", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11042"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asheville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28803"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roanoke", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "24016"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Patient Transfer Program for Transitioning From Exubera\u00ae (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere\u00ae Insulin (Insulin Human [rDNA Origin]) Inhalation Powder", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Data will be analyzed utilizing a listing with descriptive statistics, where applicable", 
                "measure": "The main objective of this trial is to monitor safety  outcomes and collect safety information on TI Inhalation Powder in subjects whose treatment has been converted from Exubera to TI Inhalation Powder.", 
                "safety_issue": "No", 
                "time_frame": "72 months"
            }, 
            {
                "description": "Data will be analyzed utilizing a listing with descriptive statistics, where applicable", 
                "measure": "Safety variables monitored will include all adverse events (AEs)and serious adverse events (SAEs)- throughout trial duration", 
                "safety_issue": "No", 
                "time_frame": "72 months"
            }, 
            {
                "description": "Data will be analyzed utilizing a listing with descriptive statistics, where applicable", 
                "measure": "Physical examination findings", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months"
            }, 
            {
                "description": "Data will be analyzed utilizing a listing with descriptive statistics, where applicable", 
                "measure": "Clinical laboratory tests", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months"
            }, 
            {
                "description": "Data will be analyzed utilizing a listing with descriptive statistics, where applicable", 
                "measure": "Chest x-rays", 
                "safety_issue": "No", 
                "time_frame": "Annually"
            }, 
            {
                "description": "Data will be analyzed utilizing a listing with descriptive statistics, where applicable", 
                "measure": "Pulmonary Function Tests - spirometry (FEV1, FVC and FEV1/FVC)", 
                "safety_issue": "No", 
                "time_frame": "Every six months up to month 60 then annually"
            }, 
            {
                "description": "Data will be analyzed utilizing a listing with descriptive statistics, where applicable", 
                "measure": "Pulmonary Function Tests- DLco", 
                "safety_issue": "No", 
                "time_frame": "Every six months up to month 60"
            }, 
            {
                "description": "Data will be analyzed utilizing a listing with descriptive statistics, where applicable", 
                "measure": "Pulmonary Function Tests - TLC", 
                "safety_issue": "No", 
                "time_frame": "Every six months up to month 60"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798914"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mannkind Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mannkind Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2008", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}